5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Hypocalcemia O
: O
Life O
threatening O
events O
and O
fatal O
outcomes O
were O
reported O
. O

Hypocalcemia O
can O
prolong O
QT O
interval O
, O
lower O
the O
threshold O
for O
seizures O
, O
and O
cause O
hypotension O
, O
worsening O
heart O
failure O
, O
and/or O
arrhythmia O
. O

Monitor O
serum O
calcium O
carefully O
for O
the O
occurrence O
of O
hypocalcemia O
during O
treatment O
( O
2.4 O
, O
5.1 O
) O
* O
Upper O
Gastrointestinal O
( O
GI O
) O
Bleeding O
: O
Patients O
with O
risk O
factors O
for O
upper O
GI O
bleeding O
may O
be O
at O
increased O
risk O
. O

Monitor O
patients O
and O
promptly O
evaluate O
and O
treat O
any O
suspected O
GI O
bleeding O
. O

( O
5.2 O
) O
* O
Hypotension O
, O
Worsening O
Heart O
Failure O
and/or O
Arrhythmias O
: O
In O
postmarketing O
safety O
surveillance O
, O
isolated O
, O
idiosyncratic O
cases O
of O
hypotension O
, O
worsening O
heart O
failure O
, O
and/or O
arrhythmia O
have O
been O
reported O
in O
patients O
with O
impaired O
cardiac O
function O
. O

( O
5.3 O
) O
* O
Adynamic O
B O
one O
D O
isease O
: O
May O
develop O
if O
iPTH O
levels O
are O
suppressed O
below O
100 O
pg/mL O
. O

( O
5.4 O
) O
5.1 O
Hypocalcemia O
Sensipar O
lowers B-NonOSE_AE
serum I-NonOSE_AE
calcium I-NonOSE_AE
and O
can O
lead O
to O
hypocalcemia B-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Significant O
lowering B-NonOSE_AE
of I-NonOSE_AE
serum I-NonOSE_AE
calcium I-NonOSE_AE
can O
cause O
paresthesias B-NonOSE_AE
, O
myalgias B-NonOSE_AE
, O
muscle B-NonOSE_AE
spasms I-NonOSE_AE
, O
tetany B-NonOSE_AE
, O
seizures B-NonOSE_AE
, O
QT B-NonOSE_AE
interval I-NonOSE_AE
prolongation I-NonOSE_AE
and O
ventricular B-NonOSE_AE
arrhythmia I-NonOSE_AE
. O

Life O
threatening O
events O
and O
fatal B-NonOSE_AE
outcomes O
associated O
with O
hypocalcemia B-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
treated O
with O
Sensipar O
, O
including O
in O
pediatric O
patients O
. O

The O
safety O
and O
effectiveness O
of O
Sensipar O
have O
not O
been O
established O
in O
pediatric O
patients O
[ O
see O
Pediatric O
Use O
( O
8.4 O
) O
] O
. O

Sensipar O
is O
not O
indicated O
for O
patients O
with O
CKD B-Not_AE_Candidate
not O
on O
dialysis O
[ O
see O
I O
ndications O
and O
Usage O
( O
1 O
) O
] O
. O

In O
patients O
with O
secondary B-Not_AE_Candidate
HPT I-Not_AE_Candidate
and O
CKD B-Not_AE_Candidate
not O
on O
dialysis O
, O
the O
long O
term O
safety O
and O
efficacy O
of O
Sensipar O
have O
not O
been O
established O
. O

Clinical O
studies O
indicate O
that O
Sensipar-treated O
patients O
with O
CKD B-Not_AE_Candidate
not O
on O
dialysis O
have O
an O
increased O
risk O
for O
hypocalcemia B-NonOSE_AE
compared O
with O
Sensipar-treated O
patients O
with O
CKD B-Not_AE_Candidate
on O
dialysis O
, O
which O
may O
be O
due O
to O
lower O
baseline O
calcium O
levels O
. O

In O
a O
phase O
3 O
study O
of O
32 O
weeks O
duration O
and O
including O
404 O
patients O
with O
CKD B-Not_AE_Candidate
not O
on O
dialysis O
( O
302 O
cinacalcet O
, O
102 O
placebo O
) O
, O
in O
which O
the O
median O
dose O
for O
cinacalcet O
was O
60 O
mg O
per O
day O
at O
the O
completion O
of O
the O
study O
, O
80 O
% O
of O
Sensipar-treated O
patients O
experienced O
at O
least O
one O
serum B-OSE_Labeled_AE
calcium I-OSE_Labeled_AE
value I-OSE_Labeled_AE
< I-OSE_Labeled_AE
8 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
compared O
with O
5 O
% O
of O
patients O
receiving O
placebo O
. O

QT O
Interval O
Prolongation O
and O
Ventricular O
Arrhythmia O
Decreases B-NonOSE_AE
in I-NonOSE_AE
serum I-NonOSE_AE
calcium I-NonOSE_AE
can O
also O
prolong B-NonOSE_AE
the I-NonOSE_AE
QT I-NonOSE_AE
interval I-NonOSE_AE
, O
potentially O
resulting O
in O
ventricular B-NonOSE_AE
arrhythmia I-NonOSE_AE
. O

Cases O
of O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
and O
ventricular B-OSE_Labeled_AE
arrhythmia I-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
treated O
with O
Sensipar O
. O

Patients O
with O
congenital B-Not_AE_Candidate
long I-Not_AE_Candidate
QT I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
, O
history O
of O
QT B-Not_AE_Candidate
interval I-Not_AE_Candidate
prolongation I-Not_AE_Candidate
, O
family O
history O
of O
long B-Not_AE_Candidate
QT I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
or O
sudden B-Not_AE_Candidate
cardiac I-Not_AE_Candidate
death I-Not_AE_Candidate
, O
and O
other O
conditions O
that O
predispose O
to O
QT B-Not_AE_Candidate
interval I-Not_AE_Candidate
prolongation I-Not_AE_Candidate
and O
ventricular B-Not_AE_Candidate
arrhythmia I-Not_AE_Candidate
may O
be O
at O
increased O
risk O
for O
QT B-NonOSE_AE
interval I-NonOSE_AE
prolongation I-NonOSE_AE
and O
ventricular B-NonOSE_AE
arrhythmias I-NonOSE_AE
if O
they O
develop O
hypocalcemia B-NonOSE_AE
due O
to O
Sensipar O
. O

Closely O
monitor O
corrected O
serum O
calcium O
and O
QT O
interval O
in O
patients O
at O
risk O
receiving O
Sensipar O
. O

Seizures O
In O
clinical O
studies O
, O
seizures B-OSE_Labeled_AE
( O
primarily O
generalized O
or O
tonic-clonic O
) O
were O
observed O
in O
1.4 O
% O
( O
43/3049 O
) O
of O
Sensipar-treated O
patients O
and O
0.7 O
% O
( O
5/687 O
) O
of O
placebo-treated O
patients O
. O

While O
the O
basis O
for O
the O
reported O
difference O
in O
seizure B-NonOSE_AE
rate O
is O
not O
clear O
, O
the O
threshold B-NonOSE_AE
for I-NonOSE_AE
seizures I-NonOSE_AE
is I-NonOSE_AE
lowered I-NonOSE_AE
by O
significant O
reductions B-NonOSE_AE
in I-NonOSE_AE
serum I-NonOSE_AE
calcium I-NonOSE_AE
levels I-NonOSE_AE
. O

Monitor O
serum O
calcium O
levels O
in O
patients O
with O
seizure B-Not_AE_Candidate
disorders I-Not_AE_Candidate
receiving O
Sensipar O
. O

Concurrent O
administration O
of O
Sensipar O
with O
calcium B-NonOSE_AE
- I-NonOSE_AE
lowering I-NonOSE_AE
drugs I-NonOSE_AE
including O
other O
calcium-sensing O
receptor O
agonists O
could O
result O
in O
severe B-NonOSE_AE
hypocalcemia I-NonOSE_AE
. O

Closely O
monitor O
serum O
calcium O
in O
patients O
receiving O
Sensipar O
and O
concomitant O
therapies O
known O
to O
lower B-NonOSE_AE
serum I-NonOSE_AE
calcium I-NonOSE_AE
levels I-NonOSE_AE
. O

Educate O
patients O
on O
the O
symptoms O
of O
hypocalcemia B-NonOSE_AE
and O
advise O
them O
to O
contact O
a O
healthcare O
provider O
if O
they O
occur O
. O

If O
corrected B-NonOSE_AE
serum I-NonOSE_AE
calcium I-NonOSE_AE
falls I-NonOSE_AE
below I-NonOSE_AE
the I-NonOSE_AE
lower I-NonOSE_AE
limit I-NonOSE_AE
of I-NonOSE_AE
normal I-NonOSE_AE
or O
symptoms O
of O
hypocalcemia B-NonOSE_AE
develop O
, O
start O
or O
increase B-NonOSE_AE
calcium I-NonOSE_AE
supplementation I-NonOSE_AE
( O
including O
calcium O
, O
calcium-containing O
phosphate O
binders O
, O
and/or O
vitamin O
D O
sterols O
or O
increases O
in O
dialysate O
calcium O
concentration O
) O
. O

Sensipar O
dose O
reduction O
or O
discontinuation O
of O
Sensipar O
may O
be O
necessary O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

5.2 O
Upper O
Gastrointestinal O
Bleeding O
Cases O
of O
gastrointestinal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
, O
mostly O
upper B-OSE_Labeled_AE
gastrointestinal I-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
, O
have O
occurred O
in O
patients O
using O
calcimimetics O
, O
including O
Sensipar O
, O
from O
postmarketing O
and O
clinical O
trial O
sources O
. O

The O
exact O
cause O
of O
GI O
bleeding O
in O
these O
patients O
is O
unknown O
. O

Patients O
with O
risk O
factors O
for O
upper B-Not_AE_Candidate
GI I-Not_AE_Candidate
bleeding I-Not_AE_Candidate
( O
such O
as O
known O
gastritis B-Not_AE_Candidate
, O
esophagitis B-Not_AE_Candidate
, O
ulcers B-Not_AE_Candidate
or O
severe O
vomiting B-Not_AE_Candidate
) O
may O
be O
at O
increased O
risk O
for O
GI B-NonOSE_AE
bleeding I-NonOSE_AE
when O
receiving O
Sensipar O
treatment O
. O

Monitor O
patients O
for O
worsening O
of O
common O
GI B-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
of O
nausea B-NonOSE_AE
and O
vomiting B-NonOSE_AE
associated O
with O
Sensipar O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
and O
for O
signs O
and O
symptoms O
of O
GI B-NonOSE_AE
bleeding I-NonOSE_AE
and O
ulcerations B-NonOSE_AE
during O
Sensipar O
therapy O
. O

Promptly O
evaluate O
and O
treat O
any O
suspected O
GI B-NonOSE_AE
bleeding I-NonOSE_AE
. O

5.3 O
Hypotension O
, O
Worsening O
Heart O
Failure O
and/or O
Arrhythmias O
In O
postmarketing O
safety O
surveillance O
, O
isolated O
, O
idiosyncratic O
cases O
of O
hypotension B-OSE_Labeled_AE
, O
worsening B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
and/or O
arrhythmia B-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
with O
impaired B-Not_AE_Candidate
cardiac I-Not_AE_Candidate
function I-Not_AE_Candidate
, O
in O
which O
a O
causal O
relationship O
to O
Sensipar O
could O
not O
be O
completely O
excluded O
and O
which O
may O
be O
mediated O
by O
reductions B-NonOSE_AE
in I-NonOSE_AE
serum I-NonOSE_AE
calcium I-NonOSE_AE
levels I-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

5.4 O
Adynamic O
Bone O
Disease O
Adynamic B-NonOSE_AE
bone I-NonOSE_AE
disease I-NonOSE_AE
may O
develop O
if O
iPTH B-NonOSE_AE
levels I-NonOSE_AE
are I-NonOSE_AE
suppressed I-NonOSE_AE
below I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
pg I-NonOSE_AE
/ I-NonOSE_AE
mL I-NonOSE_AE
. O

One O
clinical O
study O
evaluated O
bone O
histomorphometry O
in O
patients O
treated O
with O
Sensipar O
for O
1 O
year O
. O

Three O
patients O
with O
mild O
hyperparathyroid B-Not_AE_Candidate
bone I-Not_AE_Candidate
disease I-Not_AE_Candidate
at O
the O
beginning O
of O
the O
study O
developed O
adynamic B-OSE_Labeled_AE
bone I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
during O
treatment O
with O
Sensipar O
. O

Two O
of O
these O
patients O
had O
iPTH B-OSE_Labeled_AE
levels I-OSE_Labeled_AE
below I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
pg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mL I-OSE_Labeled_AE
at O
multiple O
time O
points O
during O
the O
study O
. O

In O
three O
6-month O
, O
phase O
3 O
studies O
conducted O
in O
patients O
with O
CKD B-Not_AE_Candidate
on O
dialysis O
, O
11 O
% O
of O
patients O
treated O
with O
Sensipar O
had O
mean O
iPTH B-OSE_Labeled_AE
values I-OSE_Labeled_AE
below I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
pg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mL I-OSE_Labeled_AE
during O
the O
efficacy-assessment O
phase O
. O

If O
iPTH B-NonOSE_AE
levels I-NonOSE_AE
decrease I-NonOSE_AE
below O
150 O
pg/mL O
in O
patients O
treated O
with O
Sensipar O
, O
the O
dose O
of O
Sensipar O
and/or O
vitamin O
D O
sterols O
should O
be O
reduced O
or O
therapy O
discontinued O
. O

